Dxcover Ltd Joins in Recognizing July 17 2024 as #GBMDay in the US

Company establishing US operations in Nashville TN

GLASGOW, Scotland & NASHVILLE, Tenn.--(BUSINESS WIRE)--Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis (MOSA-Dx) for early detection of solid tumor cancers, joins in recognizing July 17, 2024 as “Glioblastoma Awareness Day” in the US. The 118^th Congress recently passed a bi-partisan resolution calling for greater public awareness of glioblastoma, honors those who have been impacted by the disease and supports efforts which improve the long-term prognosis for and quality of life for those impacted by the disease. The entirety of the Resolution can be found here https://www.congress.gov/bill/118th-congress/senate-resolution/735/text.

While considered a rare cancer, Glioblastoma (GBM) is one of the most complex, deadly and treatment-resistant cancers, accounting for approximately 50% percent of all primary malignant brain tumor diagnoses each year. Once diagnosed, GBM survival rates are often a few months and, despite new therapeutic efforts, have not improved over decades. Unfortunately, therapeutic treatments have not yet significantly improved patient survival nor quality of life.

Chief Executive Officer Professor Matthew J. Baker said, "Dxcover was founded to enable the earliest detection of cancer. We believe that the combination of Dxcover’s multi-omic spectral analysis and machine learning will lead to the greatest impact on patient recovery, lifespan and quality of life post-diagnosis. We recently launched our EMBRACE study, our UK and pan-Europe 2,200 patient performance evaluation of the Dxcover® Brain Cancer Liquid Biopsy which will enable CE marking and provide a much-needed tool for patients."

The company has published in both retrospective and prospective clinical studies the Dxcover PANAROMIC™ platform’s detection of brain tumors as small as 0.2 cm³. The company is seeking clinical trial partners to demonstrate the platform’s brain and other solid tumor early detection capabilities in the United States.

About Dxcover Limited

The Dxcover PANAROMIC platform utilizes multi-omic spectral analysis to detect cancer. This technology goes beyond traditional methods by analyzing signals missed by current cell-free DNA testing. Dxcover's PANAROMIC platform has achieved impressive results, including 99% specificity for early-stage tumors and validation in over 3,000 patient samples across various cancers. This versatile platform can be adapted for high sensitivity (ruling out cancer) or high specificity (ruling in cancer), making it a valuable tool for clinicians. Additionally, Dxcover's platform is patented in the US, EU, and China. It recently incorporated in the US and is in the process of establishing US operations in Nashville TN.

For further information https://www.dxcover.com/science